Accord Plasma (Intas Pharmaceuticals) Acquires Prothya Biosolutions Belgium

Intas Pharmaceuticals / Accord BioPharma Acquires UDENYCA Franchise from Coherus BioSciences

August 6, 2025

Pharmaceuticals

Intas Pharmaceuticals, via its U.S. specialty division Accord BioPharma, completed the acquisition of the UDENYCA (pegfilgrastim-cbqv) franchise from Coherus BioSciences. The asset sale expands Accord/Intas' FDA-approved biosimilar portfolio—particularly in oncology supportive care—and brings key Coherus commercial and manufacturing personnel into Accord to support continuity and growth in the U.S. and international markets.

Permira Partners with Marcucci Family, ADIA and Ampersand to Combine Kedrion and BPL

September 1, 2022

Pharmaceuticals

Funds advised by Permira, in partnership with the Marcucci family and supported by a subsidiary of ADIA and Ampersand Capital Partners, completed the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory (BPL) to create a global leader in plasma derivatives and rare disease medicines. The combined company will be headquartered in Italy, generate over €1.1 billion in revenue, and expand its global footprint (including a ~75 US plasma center footprint); Ugo Di Francesco has been appointed CEO effective January 2023.

Advent International and Warburg Pincus Acquire Baxter's BioPharma Solutions to Form Simtra BioPharma Solutions

October 2, 2023

Pharmaceuticals

Advent International and Warburg Pincus completed the acquisition of Baxter International's BioPharma Solutions (BPS) business for $4.25 billion in cash, creating a standalone CDMO named Simtra BioPharma Solutions. Simtra will operate manufacturing sites in Bloomington, Indiana and Halle, Germany, establish a corporate headquarters in New Jersey, and employ approximately 1,700 people to provide sterile contract manufacturing and parenteral delivery services to pharma and biotech customers.

Arcline Investment Management Acquires Polypeptide Therapeutic Solutions (PTS)

April 27, 2021

Biotechnology

Arcline Investment Management, a growth-oriented private equity firm, has acquired Polypeptide Therapeutic Solutions, S.L. (PTS) from Columbus Venture Partners. PTS is a Valencia-based GMP CDMO specializing in polyamino-acid (PAA) nanoparticle encapsulation and related drug-delivery services; Arcline plans to scale GMP production and expand the company's technology portfolio to support mRNA, gene/cell therapies, biologics and vaccines.

Recipharm Acquires Arranta Bio

February 18, 2022

Biotechnology

Recipharm has acquired Arranta Bio, a US-based CDMO specializing in advanced therapy medicinal products (ATMPs), microbiome therapeutics and mRNA manufacturing, to expand its biologics and ATMP capabilities and establish a stronger US presence. Arranta Bio brings fermentation, purification, analytics and end-to-end mRNA drug substance and drug product capabilities; the transaction was expected to close around the end of March 2022.

Ampersand Capital Partners Acquires Purna Pharmaceuticals

February 12, 2026

Pharmaceuticals

Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.